Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer

Ítems similars

• Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis
  per: LIN, ZEXIN, et al.
  Publicat: (2015)
• Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies
  per: Wang, Lei, et al.
  Publicat: (2020)
• Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications
  per: Aslam, Shahzeena, et al.
  Publicat: (2013)
• Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer
  per: Li, Ze, et al.
  Publicat: (2015)
• QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
  per: Ghatalia, P, et al.
  Publicat: (2015)